文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

人乳头瘤病毒相关宫颈癌预防与控制评估动态模型的进展

Advances in HPV-Associated Cervical Cancer Dynamic Modelling for Prevention and Control Evaluation.

作者信息

He Yuxi, Ni Han, Kuang Wentao, Fu Liuyi, Yi Shanghui, Zha Wenting, Lyu Yuan

机构信息

Hunan Key Laboratory of Molecular Epidemiology, School of Medicine, Hunan Normal University, Changsha City, Hunan Province, China.

出版信息

China CDC Wkly. 2025 Feb 7;7(6):225-229. doi: 10.46234/ccdcw2025.035.


DOI:10.46234/ccdcw2025.035
PMID:39975937
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11832444/
Abstract

Cervical cancer is a common malignancy in women, with persistent human papillomavirus (HPV) infection as its primary cause. Understanding the progression from HPV infection to cervical cancer is crucial. Mathematical models play a key role in converting clinical trial data into long-term health forecasts, helping decision-makers tackle challenges posed by limited data and uncertain outcomes. This paper reviews transmission dynamics models and advancements in simulating HPV transmission leading to cervical cancer. It evaluates preventive and control measures, focusing on the impact of HPV vaccination across different vaccine types, doses, age groups, and both genders. These model-based assessments aim to provide insights for developing effective strategies to prevent and control HPV-related cervical cancer.

摘要

宫颈癌是女性常见的恶性肿瘤,主要由持续性人乳头瘤病毒(HPV)感染引起。了解从HPV感染到宫颈癌的进展至关重要。数学模型在将临床试验数据转化为长期健康预测方面发挥着关键作用,有助于决策者应对数据有限和结果不确定所带来的挑战。本文综述了传播动力学模型以及在模拟导致宫颈癌的HPV传播方面的进展。它评估了预防和控制措施,重点关注不同疫苗类型、剂量、年龄组以及男女两性中HPV疫苗接种的影响。这些基于模型的评估旨在为制定预防和控制HPV相关宫颈癌的有效策略提供见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c139/11832444/0118a3184318/ccdcw-7-6-225-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c139/11832444/0118a3184318/ccdcw-7-6-225-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c139/11832444/0118a3184318/ccdcw-7-6-225-1.jpg

相似文献

[1]
Advances in HPV-Associated Cervical Cancer Dynamic Modelling for Prevention and Control Evaluation.

China CDC Wkly. 2025-2-7

[2]
Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.

Lancet Infect Dis. 2021-11

[3]
Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.

J Manag Care Pharm. 2010-4

[4]
Population-level impact of switching to 1-dose human papillomavirus vaccination in high-income countries: examining uncertainties using mathematical modeling.

J Natl Cancer Inst Monogr. 2024-11-1

[5]
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.

Cochrane Database Syst Rev. 2018-5-9

[6]
Switching from a 2-dose to a 1-dose program of gender-neutral routine vaccination against human papillomavirus in Canada: a mathematical modelling analysis.

CMAJ. 2024-10-6

[7]
Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study.

Lancet Oncol. 2022-11

[8]
Potential population-level effectiveness of one-dose HPV vaccination in low-income and middle-income countries: a mathematical modelling analysis.

Lancet Public Health. 2023-10

[9]
Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study.

Vaccine. 2018-3-15

[10]
Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial.

Lancet Oncol. 2022-7

引用本文的文献

[1]
Cervical Cancer Screening, HPV Vaccination, and Cervical Cancer Elimination.

JAMA Netw Open. 2025-8-1

本文引用的文献

[1]
Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis.

BMC Med. 2023-8-28

[2]
Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong.

Hum Vaccin Immunother. 2023-8-1

[3]
The Clinical and Economic Impact of a Nonavalent Versus Bivalent Human Papillomavirus National Vaccination Program in Taiwan.

Value Health Reg Issues. 2022-11

[4]
Assessing the Health and Economic Outcomes of a 9-Valent HPV Vaccination Program in the United Kingdom.

J Health Econ Outcomes Res. 2022-6-6

[5]
HPV and the Risk of HIV Acquisition in Women.

Front Cell Infect Microbiol. 2022

[6]
Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.

Lancet Infect Dis. 2021-11

[7]
Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium.

Front Pharmacol. 2021-4-12

[8]
A Review of Cervical Cancer: Incidence and Disparities.

J Natl Med Assoc. 2020-4

[9]
Will HPV vaccination prevent cervical cancer?

J R Soc Med. 2020-1-21

[10]
Human Papilloma Virus-Associated Cervical Cancer and Health Disparities.

Cells. 2019-6-21

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索